Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) have been given a consensus rating of “Hold” by the six analysts that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $12.00.
PGNX has been the subject of several recent research reports. BidaskClub downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 4th. ValuEngine cut shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th.
A number of institutional investors have recently added to or reduced their stakes in PGNX. Duncker Streett & Co. Inc. purchased a new position in Progenics Pharmaceuticals during the fourth quarter worth about $33,000. Cubist Systematic Strategies LLC boosted its holdings in Progenics Pharmaceuticals by 1,825.1% during the second quarter. Cubist Systematic Strategies LLC now owns 10,126 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 9,600 shares during the last quarter. Bank of Montreal Can boosted its holdings in Progenics Pharmaceuticals by 437.9% during the second quarter. Bank of Montreal Can now owns 12,286 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 10,002 shares during the last quarter. Jane Street Group LLC purchased a new position in Progenics Pharmaceuticals during the second quarter worth about $148,000. Finally, Stifel Financial Corp boosted its holdings in Progenics Pharmaceuticals by 9.0% during the third quarter. Stifel Financial Corp now owns 38,916 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 3,207 shares during the last quarter. Institutional investors and hedge funds own 78.49% of the company’s stock.
NASDAQ:PGNX opened at $4.46 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.76 and a quick ratio of 3.76. The firm has a 50-day moving average of $4.91 and a 200-day moving average of $5.03. The company has a market cap of $385.44 million, a PE ratio of -5.31 and a beta of 2.68. Progenics Pharmaceuticals has a one year low of $3.42 and a one year high of $6.37.
Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. The company had revenue of $5.61 million during the quarter, compared to the consensus estimate of $7.05 million. Progenics Pharmaceuticals had a negative net margin of 311.63% and a negative return on equity of 91.96%. On average, equities research analysts expect that Progenics Pharmaceuticals will post -1 earnings per share for the current fiscal year.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company’s product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Recommended Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Progenics Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
